Abstracts tagged "Adverse events"

Abstract Number: 1916 • 2018 ACR/ARHP Annual Meeting
Neutrophil-to-Lymphocyte Ratio Prospectively Predicts the Development of Rheumatic Immune-Related Adverse Events from PD-1 Inhibitor Therapy
Christopher McMaster^1,2, David Liew^3,4, Pallavi Shamdasani⁵, Jessica Leung^3,4, Albert Frauman^6,7, Jonathan Cebon^7,8 and Russell Buchanan^4,9, ¹Department of Clinical Pharmacology and Therapeutics, Austin Health, Heidelberg, Australia, ²Health and Biomedical Informatics Centre, University of Melbourne, Parkville, Australia, ³Medicine, University of Melbourne, Parkville VIC, Australia, ⁴Rheumatology, Austin Health, Heidelberg VIC, Australia, ⁵Department of Rheumatology, Austin Health, Heidelberg, Australia, ⁶Department of Clinical Pharmacology and Therapeutics, Austin Health, Melbourne, Australia, ⁷Medicine, University of Melbourne, Melbourne, Australia, ⁸Olivia Newton-John Cancer Wellness & Research Centre, Melbourne, Australia, ⁹Medicine, University of Melbourne, Parkville, Australia
Background/Purpose: Rheumatic immune-related adverse events (irAEs) from PD-1 inhibitor immune checkpoint immunotherapy can not only lead to cessation of immunotherapy, but also can be disabling…
Abstract Number: 2744 • 2018 ACR/ARHP Annual Meeting
Giant-Cell Arteritis: Is Glucocorticoid-Sparing Treatment Still Relevant? a Retrospective Study
Segolene Perrineau¹, Romain Paule², Pierre Charles³, Martine GAYRAUD⁴, Benjamin Terrier^1,5, Loïc Guillevin¹, Luc Mouthon^1,5 and Alexis Régent^2,5, ¹Department of Internal Medicine, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (APHP), Université Paris Descartes, PARIS, France, ²Department of Internal Medicine, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (APHP), Université Paris Descartes, Paris, France, ³Department of Internal Medicine, Institut Mutualiste Montsouris, Paris, France, ⁴Department of Internal Medicine, Institut Mutualiste Montsouris, PARIS, France, ⁵Institut Cochin, INSERM U1016, CNRS UMR 8104, PARIS, France
Background/Purpose: Giant-cell arteritis (GCA) is the most common primary large-vessel vasculitis affecting patients over 50 yr. Despite frequent and severe adverse events (AEs), glucocorticoids (GCs)…
Abstract Number: 448 • 2018 ACR/ARHP Annual Meeting
Tizanidine, a Frequently Used Muscle Relaxant, Is Associated with Severe Hypotension: Role of Cytochrome P450 1A2 Inhibition in Routine Clinical Practice
Sandip Chaugai¹, Alyson Dickson², Megan Shuey², QiPing Feng², Katherine Barker², James Luther², C. Michael Stein³ and Cecilia P. Chung³, ¹Medicine, Vanderbilt University Medical Center, Nashville, TN, ²Vanderbilt University Medical Center, Nashville, TN, ³Department of Medicine, Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Tizanidine, a muscle relaxant widely used for musculoskeletal pain, can lower blood pressure and is metabolized by the cytochrome P450 1A2 (CYP1A2). As a…
Abstract Number: 1919 • 2018 ACR/ARHP Annual Meeting
Individual Short-Acting Opioids and the Risk of Opioid-Related Adverse Events in Adolescents
Cecilia P. Chung¹, S. Todd Callahan², William Cooper², William Dupont³, Katherine Murray¹, Andrew Franklin⁴, Kathi Hall⁵, Judith A. Dudley⁵, C. Michael Stein¹ and Wayne Ray⁵, ¹Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, ²Pediatrics, Vanderbilt University Medical Center, Nashville, TN, ³Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, ⁴Anesthesiology, Vanderbilt University Medical Center, Nashville, TN, ⁵Health Policy, Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Hydrocodone, codeine, oxycodone, and tramadol are frequently prescribed for moderate pain in adolescents. However, pharmacokinetic and pharmacodynamic differences between these short-acting opioids could affect…
Abstract Number: 2783 • 2018 ACR/ARHP Annual Meeting
EULAR Task Force Recommendations for a Minimum Core Set of Parameters to be Collected in Giant Cell Arteritis Registries and Databases
Lisa Ehlers¹, Johan Askling², Johannes W. J. Bijlsma³, Maria C. Cid⁴, Maurizio Cutolo⁵, Bhaskar Dasgupta⁶, Christian Dejaco^7,8, William G Dixon⁹, Nils Feltelius^10,11, Axel Finckh¹², Kate Gilbert¹³, Sarah Mackie¹⁴, Alfred Mahr¹⁵, Eric L. Matteson¹⁶, Lorna Neill¹⁷, Carlo Salvarani^18,19, Wolfgang A. Schmidt²⁰, Anja Strangfeld²¹, Ronald van Vollenhoven²² and Frank Buttgereit¹, ¹Department of Rheumatology and Clinical Immunology, Charité University Hospital Berlin, Berlin, Germany, ²Unit of Clinical Epidemiology, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden, ³Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁴University of Barcelona, Barcelona, Spain, ⁵Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, San Martino Polyclinic Hospital, Genoa, Italy, Genoa, Italy, ⁶Southend University Hospital NHS Foundation Trust, Westcliff-on-Sea, United Kingdom, ⁷Department of Rheumatology and Immunology, Medical University Graz, Graz, Austria, Graz, Austria, ⁸Rheumatology, Hospital of Bruneck, Bruneck, Italy, ⁹Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ¹⁰Medical Products Agency, Uppsala, Sweden, ¹¹Cross-Committee Task Force on Registries at the European Medicines Agency, London, United Kingdom, ¹²University Hospital of Geneva, Geneva, Switzerland, ¹³Patient Representative from PMRGCAuk, London, United Kingdom, ¹⁴NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, University of Leeds, Leeds, United Kingdom, ¹⁵Internal Medicine, Saint-Louis Hospital, Paris Diderot University, Paris, France, ¹⁶Division of Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN, ¹⁷Patient Representative from PMR-GCA Scotland, Perth, United Kingdom, ¹⁸Università di Modena e Reggio Emilia, Modena, Italy, ¹⁹Azienda USL-IRCCS di Reggio Emilia and Università di Modena e Reggio Emilia, Reggio Emilia, Italy, ²⁰Medical Center for Rheumatology and Clinical Immunology Berlin-Buch, Immanuel Krankenhaus Berlin, Berlin, Germany, ²¹Epidemiology, German Rheumatism Research Center, Berlin, Germany, ²²Amsterdam Rheumatology and Immunology Center ARC, Amsterdam, Netherlands
Background/Purpose: Giant cell arteritis (GCA) represents the most common form of primary systemic vasculitis, and is frequently associated with comorbidities related either to the disease…
Abstract Number: 552 • 2018 ACR/ARHP Annual Meeting
Drug Tolerability and Discontinuation Reasons of 7 Biologics in 4466 Treatment Courses of Rheumatoid Arthritis -the Answer Cohort Study-
Kosuke Ebina¹, Makoto Hirao², Motomu Hashimoto³, Wataru Yamamoto⁴, Akira Onishi⁵, Toru Hirano⁶, Ryota Hara⁷, Masaki Katayama⁸, Shuzo Yoshida⁹, Koji Nagai⁹, Yonsu Son¹⁰, Hideki Amuro¹⁰, Kengo Akashi¹¹, Koichi Murata³, Kosaku Murakami¹², Keiichi Yamamoto¹³ and Hideki Yoshikawa¹⁴, ¹Orthopaedic Surgery, Osaka University Graduate School of Medicine, Suita, Japan, ²Orthopaedic Surgery, Osaka University, Graduate School of Medicine, Suita, Japan, ³Department of Advanced Medicine for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁴Department of Health Information Management, Kurashiki Sweet Hospital, Okayama, Japan, ⁵Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, ⁶Department of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine, Suita, Japan, ⁷The Center for Rheumatic Diseases, Department of Orthopaedic Surgery, Nara Medical University, Kashihara, Japan, ⁸Department of Rheumatology, Osaka Red Cross Hospital, Osaka, Japan, ⁹Department of Internal Medicine (IV), Osaka Medical College, Osaka, Japan, ¹⁰First Department of Internal Medicine, Kansai Medical University, Osaka, Japan, ¹¹Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, ¹²Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ¹³Department of Medical Statistics, Osaka City University, Osaka, Japan, ¹⁴Department of Orthopedic Surgery, Osaka University Graduate School of Medicine, Suita Osaka, Japan
Background/Purpose: Drug tolerability indicates both the patient’s and doctor’s satisfaction and useful summary measure of overall treatment effectiveness and toxicity. Although more than 5 years…
Abstract Number: 2139 • 2018 ACR/ARHP Annual Meeting
Retrospective Study: Association of Hydroxychloroquine Use and Hemolytic Anemia in Patients with Low Levels of Glucose-6-Phosphate Dehydrogenase (G6PD)
Mateo Mejia Saldarriaga¹, Ivan Emil Ramirez de Oleo¹ and Beverly Johnson^2,3, ¹Internal Medicine, Jacobi Medical Center, Bronx, NY, ²Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, NY, ³Rheumatology, Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: Glucose-6-phosphate dehydrogenase deficiency (G6PD) is linked to hemolytic anemia with certain medications and is the most common enzyme deficiency worldwide. Clinical hemolysis and severity…
Abstract Number: 2955 • 2018 ACR/ARHP Annual Meeting
Risk of Neurological Adverse Events during Tumour Necrosis Factor Inhibitor Treatment for Arthritis: A Population-Based Cohort Study from Danbio and the Danish National Patient Registry
Lene Dreyer¹, Tine Iskov Kopp², Rikke Kart Jacobsen³, Melinda Magyari², Else Helene Ibfelt³, Henning Locht⁴, Finn Thorup Sellebjerg², Dorte Vendelbo Jensen⁵ and René Cordtz⁶, ¹Departments of Rheumatology and Clinical Medicine, Aalborg University Hospital and Aalborg University, 9000 Aalborg, Denmark, ²Danish Multiple Sclerosis Center, Department of Neurology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark, ³Center for Clinical Research and Prevention, Bispebjerg and Frederiksberg Hospital, Frederiksberg, Denmark, ⁴Department of Rheumatology, Frederiksberg Hospital, Copenhagen, Denmark, Copenhagen, Denmark, ⁵The DANBIO registry and the Danish Departments of Rheumatology, Copenhagen, Denmark, ⁶Center for Rheumatology and Spine Diseases, Gentofte-Rigshospitalet, Hellerup, Denmark
Background/Purpose: Tumor necrosis factor alpha inhibitors (TNFi) have successfully been used for the treatment of immune-mediated inflammatory disorders including rheumatoid arthritis (RA), psoriatic arthritis (PsA)…
Abstract Number: 960 • 2018 ACR/ARHP Annual Meeting
The Risk of Gastrointestinal Perforations Associated with Biologic Disease-Modifying Anti-Rheumatic Drugs Used in Rheumatoid Arthritis: A Nationwide Swedish Cohort Study
Andrei Barbulescu¹, Thomas Frisell¹, Johan Askling² and Bénédicte Delcoigne¹, ¹Clinical Epidemiology Unit, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden, ²Unit of Clinical Epidemiology, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Gastrointestinal (GI) perforations occur more often than expected in patients with RA. Reports indicate that tocilizumab may be associated with an increased risk of…
Abstract Number: 2141 • 2018 ACR/ARHP Annual Meeting
Development of a Pediatric Glucocorticoid Toxicity Index
Paul Brogan¹, Raymond P. Naden², Stacy P. Ardoin³, Jennifer C. Cooper⁴, Fabrizio De Benedetti⁵, Jean-Francois Dicaire⁶, Despina Eleftheriou⁷, Brian M. Feldman⁸, Jon Goldin⁹, Seth E. Karol¹⁰, Eli Miloslavsky¹¹, Fiona Price-Kuehne¹², David Skuse⁹, Constantine A. Stratakis¹³, Nicholas Webb¹⁴ and John H. Stone¹⁵, ¹Infection Inflammation and Rheumatology, UCL Institute of Child Health, and Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom, ²New Zealand Ministry of Health, New Zealand Ministry of Health, Auckland, New Zealand, ³The Ohio State University Wexner Medical Center, Columbus, OH, ⁴Pediatrics, Divison of Rheumatology, University of California, San Francisco, San Francisco, CA, ⁵IRCCS Ospedale Pediatrico Bambino Gesù, Roma, Italy, ⁶Pinnacle Inc., Quebec, QC, Canada, ⁷Infection, Inflammation and Rheumatology, UCL Institute of Child Health, London, United Kingdom, ⁸Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ⁹Psychiatry, Great Ormond Street Hospital / University College London, London, United Kingdom, ¹⁰Oncology, St. Jude's Children's Hospital, Memphis, TN, ¹¹Division of Rheumatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ¹²Rheumatology, Cambridge University Hospitals, Cambridge, United Kingdom, ¹³National Institute of Child Health and Human Development, Bethesta, MD, ¹⁴Pediatrics, Manchester University, Manchester, United Kingdom, ¹⁵Rheumatology (Medicine), Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: A Glucocorticoid Toxicity Index app (GTI 2.0) is now used as a clinical trial outcome measure in adults, but glucocorticoid (GC) toxicity issues in…
Abstract Number: 2959 • 2018 ACR/ARHP Annual Meeting
Development of a Set of Potentially Preventable Adverse Conditions Specific to Lupus: A Delphi Consensus Study
Candace H. Feldman¹, Cameron Speyer¹, Rachel Ashby², Bonnie L. Bermas³, Shamik Bhattacharyya⁴, Eliza Chakravarty⁵, Brendan Everett⁶, Elizabeth Ferucci⁷, Aimee O. Hersh⁸, Francisco Marty⁹, Joseph F. Merola¹⁰, Rosalind Ramsey-Goldman¹¹, Brad Rovin¹², Mary Beth Son¹³, Laura Tarter¹⁴, Sushrut Waikar¹⁵, Jinoos Yazdany¹⁶, Joel Weissman¹⁷ and Karen Costenbader¹, ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Obstetrics and Gynecology, Brigham and Women's Hospital, Boston, MA, ³Rheumatology, UT Southwestern, Dallas, TX, ⁴Neurology, Brigham and Women's Hospital, Boston, MA, ⁵Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Cardiology, Brigham and Women's Hospital, Boston, MA, ⁷Alaska Native Medical Center, Anchorage, AK, ⁸Pediatrics/Rheumatology, University of Utah, Salt Lake City, UT, ⁹Infectious Disease, Brigham and Women's Hospital, Boston, MA, ¹⁰Medicine, Rheumatology and Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ¹¹FSM, Northwestern University, Chicago, IL, ¹²Ohio State University Wexner Medical Center, Columbus, OH, ¹³Boston Children's Hospital, Harvard Medical School, Brookline, MA, ¹⁴Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ¹⁵Renal, Brigham and Women's Hospital, Boston, MA, ¹⁶University of California, San Francisco, San Francisco, CA, ¹⁷Brigham and Women's Hospital, Boston, MA
Background/Purpose: The U.S. Agency for Healthcare Research and Quality developed a set of general ambulatory care-sensitive conditions that may result acute care use (hospitalizations and…
Abstract Number: 1190 • 2018 ACR/ARHP Annual Meeting
Use of Biologic Drugs and Adverse Events in Patients with Rheumatic Disease: DATA from the Mexican Biologics Registry
Daniel Xibille-Friedmann¹, Sandra Miriam Carrillo -Vazquez², Sandra Sicsik Ayala³, Fedra Irazoque-Palazuelos⁴, Azucena Ramos-Sanchez⁵, Sergio Duran-Barragan⁶, Miguel A Saavedra⁷, Leonor Barile⁸ and Guadalupe Olvera⁹, ¹Research and Training Department, Servicios de Salud de Morelos, Cuernavaca, Mexico, ²Rheumatology, Hospital 1 de Octubre ISSSTE, Mexico City, Mexico, ³Rheumatology, UMAE 71 IMSS, Torreon, Mexico, Torreon, Mexico, ⁴Rheumatology Department, CMN 20 de Noviembre ISSSTE,, CDMX, Mexico, ⁵Rheumatology, CMN NE 25 IMSS, Monterrey, Mexico, ⁶Centro Universitario de Ciencias de la Salud, Instituto de Investigación en Reumatología y del Sistema Músculo Esquelético, Universidad de Guadalajara, Guadalajara, Mexico, ⁷Novartis Farmaceutica, Calz de Tlaplan 1779, Mexico, Mexico, ⁸Hospital Ángeles del Pedregal, Mexico, Mexico, ⁹Research Department, Colegio Mexicano de Reumatologia, Mexico City, Mexico
Background/Purpose: National registries of biologic drugs have proven to be valuable tools in following patients with rheumatic disease and some outcomes in real-life situations. The…
Abstract Number: 2194 • 2018 ACR/ARHP Annual Meeting
Develop a New Platform for Post-Marketing Vigilance Though Smart System of Disease Management (SSDM) Mobiles Tools: A Real World Cohort Study of RA Patients from China
Yongfu Wang¹, Hua Wei², Jing Yang³, Chun Li⁴, Rong Mu⁵, Bin Wu⁶, Hongzhi Wang⁷, Yong Wang⁸, Xiaohan Wang⁹, Huifang Guo¹⁰, Jing Xue¹¹, Jinli Ru¹², Xiafei Xin¹³, Fengxiao Zhang¹⁴, Lirong Kang¹, Hong Liu³, Xiaoling Liu¹⁵, Tong Xie¹⁶, Lingxun Shen¹⁷, Huiqin Yang¹⁸, Shouxin Li¹⁹, Fen Li²⁰, Fen Wang²¹, Rui Wu²², Yuan Liu²³, Hui Xiao²³, Yuhua Jia²³, Fei Xiao²³ and Jianlin Huang²⁴, ¹The First Affiliated Hospital of BaoTou Medical College, Baotou, China, ²Northern Jiangsu People's Hospital, Yangzhou, China, ³Department of rheumatology, Central Hospital of MianYang, Sichuan, Mian Yang, China, ⁴Peking University People's Hospital, Beijing, China, ⁵Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China, ⁶Department of Rheumatology, Chongqing Hospital of Traditional Chinese Medicine, Chongqing, China, ⁷The First Hospital of Jiaxing, Jiaxing, China, ⁸The first Hospital Affiliated to AMU (Southernwest Hospital), Chongqing, China, ⁹Department of Rheumatology and Immunology, Anyang district hospital, Anyang, China, ¹⁰The Second Hospital of Hebei Medical University, Shijiazhuang, China, ¹¹88 Jiefang Road, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China, ¹²The Second hospital of Shanxi Medical University, Taiyuan, China, ¹³Department of Rheumatology and Immunology, NingBo First Hospital, Zhejiang, Ningbo, China, ¹⁴Department of Rheumatology and Immunology, Hebei General Hospital, Shijiazhuang, China, ¹⁵The 1st Affiliated Hospital of Guangzhou University of TCM, Guangzhou, China, ¹⁶Affiliated hospital of Guangdong medical University, Zhanjiang, China, ¹⁷Union Hospital Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China, ¹⁸Wuhan No 1 Hospital, wuhan, China, ¹⁹Tongji Hospital，Tongji Medical College，Huazhong University of Science and Technology, wuhan, China, ²⁰The Second Xiangya Hospital of Central South University, Changsha, China, ²¹Department of Rheumatology, First Affiliated Hospital of Medical University Of Anhui, Hefei, China, ²²The First Affiliated Hospital of Nanchang University, Nanchang, China, ²³Shanghai Gothic Internet Technology Co., Ltd., Shanghai, China, ²⁴Department of rheumatology, The Sixth Hospital Affiliated to Sun yat-sen University, Guangzhou, China
Background/Purpose: Adverse events (AE) during treatment in RA patients are unavoidable. Monitoring AEs in real time during long-term treatment is critical for AE detection and…
Abstract Number: 2976 • 2018 ACR/ARHP Annual Meeting
Immune Checkpoint Inhibitor-Associated Myositis: A Characteristic Phenotype with a Poor Outcome Related to Concomitant Myocarditis
Celine Anquetil^1,2, Joe-Elie Salem^3,4, Benedicte Lebrun-Vignes⁵, Douglas B Johnson⁶, Andrew Mammen^7,8, Werner Stenzel⁹, Sarah Leonard-louis¹⁰, Olivier Benveniste^11,12, Javid J Moslehi³ and Yves Allenbach^2,13, ¹Internal Medicine and Clinical Immunlogy, Assistance Public - Hopitaux de Paris, Pitié-Salpêtrière University Hospital, PARIS, France, ²CDR en myologie UMR974,, Institut National de la Santé et de la Recherche Médicale, Association Institut de Myologie, PARIS, France, ³Division of Cardiovascular Medicine and Cardio-Oncology Program, Department of Medicine, Vanderbilt University Medical Center, Nasheville, TN, ⁴Department of Pharmacology, Regional Center of Pharmacovigilance, INSERM, CIC-1421, Paris, France, ⁵Department of Pharmacology, Regional Center of Pharmacovigilance, INSERM, CIC-1421, PARIS, France, ⁶Division of Oncology, Department of Medicine, Vanderbilt University Medical Center, Nasheville, TN, ⁷National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁸Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁹Charité - Universitätsmedizin, Department of Neuropathology, Berlin, Germany, Berlin, Germany, ¹⁰Département de Neuropathologie, Centre de Référence des Maladies Neuro-Musculaires Paris Est, Assistance Publique – Hôpitaux de Paris (AP-HP), Hôpital Universitaire Pitié-Salpêtrière, Paris, France, ¹¹Department of Internal Medicine and Clinical Immunology and Inflammation-Immunopathology-Biotherapy Department (I2B), Pitié-Salpêtrière University Hospital, Assistance Publique-Hôpitaux de Paris, East Paris Neuromuscular Diseases Reference Center, Paris, France, ¹²Centre de Recherche en Myologie, UMRS974, Institut National de la Santé et de la Recherche Médicale, Association Institut de Myologie, Paris, France, ¹³Internal Medicine and Clinical Immunology, Sorbonne University - Assistance Public - Hopitaux de Paris, Pitié-Salpêtrière University Hospital, Paris, France
Background/Purpose: Immune checkpoint inhibitors (ICI) are a major breakthrough in cancer treatment providing frequent durable responses and improving overall survival. Blocking immune checkpoints (Programmed cell…
Abstract Number: 1233 • 2018 ACR/ARHP Annual Meeting
Rituximab Safety in Patients with Rheumatoid Arthritis. an Eleven-Year Follow-up Observational Study
Raul Castellanos-Moreira Sr.¹, Sebastian C Rodriguez-Garcia¹, M. Victoria Hernández², Virginia Ruiz-Esquide³, Oscar Camacho Sr.¹, Andrea Cuervo¹, Julio Ramírez³, Juan Cañete¹, Jose Gomez Puerta¹ and Raimon Sanmarti¹, ¹Rheumatology Service, Hospital Clínic de Barcelona, Barcelona, Spain, ²Rheumatology, Hospital Clinic. Barcelona. Spain, Barcelona, Spain, ³Rheumatology, Hospital Clínic de Barcelona, Barcelona, Spain
Background/Purpose: Rituximab (RTX) is a chimeric monoclonal antibody approved for the treatment rheumatoid arthritis (RA) patients who failed to respond to tumor necrosis factor inhibitors.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].